Siemens Healthineers AG Unsponsored ADR (SMMNY)
OTHER OTC:SMMNY
Want to see SMMNY full AI Analyst Report?
SMMNY Stock Chart & Stats
$26.02
--
Market closed
$26.02
--
Day’s Range― - ―
52-Week Range$19.42 - $28.79
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.52K
Market Cap
$43.41B
Enterprise Value$52.50B
Total Cash (Recent Filing)$1.91B
Total Debt (Recent Filing)$15.34B
Price to Earnings (P/E)18.6
Beta1.04
Next Earnings
Jul 31, 2026EPS Estimate
0.34Next Dividend Ex-DateN/A
Dividend Yield1.98%
Share Statistics
EPS (TTM)0.83
Shares Outstanding2,256,000,000
10 Day Avg. Volume0
30 Day Avg. Volume1,521
Financial Highlights & Ratios
PEG Ratio7.41
Price to Book (P/B)2.44
Price to Sales (P/S)2.34
P/FCF Ratio24.19
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue2.41
Enterprise Value/Gross Profit5.98
Enterprise Value/Ebitda11.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.32
Revenue Forecast (FY)$27.80B
Bulls Say, Bears Say
Bulls Say
Recurring Revenue & Installed BaseSiemens Healthineers' business mixes high‑value equipment sales with recurring service, consumables and software subscriptions. This installed‑base pull‑through creates durable, predictable revenue and margin support, smoothing cycles in capital spending and underpinning long‑term cash generation.
Strong Cash Generation & FCF ConversionSustained OCF and high free cash flow conversion provide the company durable internal funding for R&D, capital expenditures, dividends and debt servicing. Reliable FCF supports strategic investment and financial flexibility despite cyclical pressure on equipment sales.
Imaging And Precision Therapy ExecutionConsistent mid‑single digit growth, a healthy book‑to‑bill and strong imaging margins demonstrate competitive product leadership and commercial momentum. These durable operational strengths drive recurring service, spare parts demand and support margin sustainability over the medium term.
Bears Say
China Diagnostics DisruptionVolume‑based procurement and reimbursement cuts in China are structural, reducing prices, volumes and profit conversion for Diagnostics. Given China's size for diagnostics demand, this creates a multi‑quarter earnings and consumables headwind that may depress segment revenue and margins.
Sharp TTM Revenue DeclineA pronounced year‑on‑year revenue decline weakens the growth profile and reduces operating leverage. Even with healthy margins, sustained revenue contraction can constrain reinvestment, slow installed‑base expansion and limit long‑term free cash flow growth if the trend persists.
Material Leverage Limiting FlexibilityElevated debt relative to equity and low OCF‑to‑debt coverage reduce financial flexibility to absorb cyclical shocks or fund large strategic initiatives. This constrains balance sheet optionality, raises refinancing and covenant risk, and can limit M&A or sustained extra capital returns under prolonged softness.
Siemens Healthineers AG Unsponsored ADR News
SMMNY FAQ
What was Siemens Healthineers AG Unsponsored ADR’s price range in the past 12 months?
Siemens Healthineers AG Unsponsored ADR lowest stock price was $19.42 and its highest was $28.79 in the past 12 months.
What is Siemens Healthineers AG Unsponsored ADR’s market cap?
Siemens Healthineers AG Unsponsored ADR’s market cap is $43.41B.
When is Siemens Healthineers AG Unsponsored ADR’s upcoming earnings report date?
Siemens Healthineers AG Unsponsored ADR’s upcoming earnings report date is Jul 31, 2026 which is in 55 days.
How were Siemens Healthineers AG Unsponsored ADR’s earnings last quarter?
Siemens Healthineers AG Unsponsored ADR released its earnings results on May 07, 2026. The company reported $0.312 earnings per share for the quarter, beating the consensus estimate of $0.294 by $0.018.
Is Siemens Healthineers AG Unsponsored ADR overvalued?
According to Wall Street analysts Siemens Healthineers AG Unsponsored ADR’s price is currently Overvalued.
Does Siemens Healthineers AG Unsponsored ADR pay dividends?
Siemens Healthineers AG Unsponsored ADR pays a Annually dividend of $0.521 which represents an annual dividend yield of 1.98%. See more information on Siemens Healthineers AG Unsponsored ADR dividends here
What is Siemens Healthineers AG Unsponsored ADR’s EPS estimate?
Siemens Healthineers AG Unsponsored ADR’s EPS estimate is 0.34.
How many shares outstanding does Siemens Healthineers AG Unsponsored ADR have?
Siemens Healthineers AG Unsponsored ADR has 2,256,000,000 shares outstanding.
What happened to Siemens Healthineers AG Unsponsored ADR’s price movement after its last earnings report?
Siemens Healthineers AG Unsponsored ADR reported an EPS of $0.312 in its last earnings report, beating expectations of $0.294. Following the earnings report the stock price went down -4.553%.
Which hedge fund is a major shareholder of Siemens Healthineers AG Unsponsored ADR?
Currently, no hedge funds are holding shares in SMMNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Siemens Healthineers AG Unsponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.89%
12-Months-Change
Fundamentals
Return on Equity
11.59%
Trailing 12-Months
Asset Growth
1.91%
Trailing 12-Months
Company Description
Siemens Healthineers AG Unsponsored ADR
Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers in Germany, the United States, rest of Europe, CIS, Africa, the Middle East, the Americas, the Asia Pacific, Japan, and China. It operates in four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment offers magnetic resonance imaging, computed tomography, X-ray, molecular imaging, and ultrasound systems; and software solutions to support the reading and structured reporting of diagnostic images from different modalities. Its Diagnostics segment provides in-vitro diagnostic products and services to healthcare providers in the fields of general and specialty laboratory, and point-of-care diagnostics; and workflow solutions for laboratories and informatics products. The Varian segment offers microwave, cryoablation, and embolization technologies, as well as clinical professional services for cancer care that support oncology departments in hospitals and clinics; and customized support for cancer care operations. Its Advanced Therapies segment provides products that are designed to support image-guided minimally invasive clinical procedures in various areas, such as cardiology, neurology, and oncology; angiography systems and mobile C-arms; and AI-powered clinical applications. It also offers essential technical customer service, such as maintenance and repair; spare parts; medical equipment performance management; training; clinical education and e-learning; planning and design; financing; asset management; and managed departmental services for laboratories and healthcare facilities, as well as healthcare consulting, products, and services. The company was founded in 1896 and is headquartered in Forchheim, Germany. Siemens Healthineers AG is a subsidiary of Siemens Aktiengesellschaft.
SMMNY Company Deck
SMMNY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mix of strong operational performance in Imaging and Precision Therapy (solid growth, margin expansion ex-headwinds, strong Americas performance, product and partnership momentum, and a Moody's investment-grade rating) offset by significant challenges in Diagnostics driven by China-specific structural changes (VBP and reimbursement reductions), tariff and FX headwinds, and near-term guidance caution for Q2. Management emphasized that core synergies and operational improvements largely offset macro headwinds in Q1 and confirmed the full-year outlook, but Diagnostics and China pose material, near-term headwinds that may temper segment-level performance.View all SMMNY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---